137 related articles for article (PubMed ID: 6139346)
21. Effects of the novel neuroprotective agent, riluzole, on human brain function and behavior: I. Double-blind, placebo-controlled EEG mapping and psychometric studies under normoxia.
Saletu B; Grünberger J; Anderer P; Linzmayer L
Methods Find Exp Clin Pharmacol; 1996; 18(1):55-66. PubMed ID: 8721257
[TBL] [Abstract][Full Text] [Related]
22. Clinical-pharmacological study with the two isomers (d-, l-) of fenfluramine and its comparison with chlorpromazine and d-amphetamine: psychometric and psychophysiological evaluation.
Grünberger J; Saletu B; Linzmayer L; Barbanoj MJ
Methods Find Exp Clin Pharmacol; 1993 Jun; 15(5):313-28. PubMed ID: 8412415
[TBL] [Abstract][Full Text] [Related]
23. Classification and bioavailability studies with WE 941 by quantitative pharmaco-EEG and clinical analyses.
Saletu B; Grünberger J; Volavka J; Berner P
Arzneimittelforschung; 1979; 29(4):700-4. PubMed ID: 582772
[TBL] [Abstract][Full Text] [Related]
24. [A quantitative pharmaco-EEG study on psychotropic properties of cerebral metabolic enhancers: comparison between young and elderly healthy volunteers].
Nobuhara K
Seishin Shinkeigaku Zasshi; 1993; 95(5):392-416. PubMed ID: 8356168
[TBL] [Abstract][Full Text] [Related]
25. Classification and assessment of cerebral bioavailability of lopirazepam (D-12524) by quantitative EEG and psychometric analysis.
Saletu B; Grünberger J; Linzmayer L; Stadler R
Arzneimittelforschung; 1980; 30(3):513-8. PubMed ID: 6104496
[TBL] [Abstract][Full Text] [Related]
26. Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteers.
Allain H; Tessier C; Bentué-Ferrer D; Tarral A; Le Breton S; Gandon M; Bouhours P
Psychopharmacology (Berl); 2003 Feb; 165(4):419-29. PubMed ID: 12459926
[TBL] [Abstract][Full Text] [Related]
27. Classification and determination of pharmacodynamics of a new antihypoxidotic drug, vinconate, by pharmaco-EEG and psychometry.
Saletu B; Grünberger J; Linzmayer L; Wittek R
Arch Gerontol Geriatr; 1984 Jul; 3(2):127-46. PubMed ID: 6476974
[TBL] [Abstract][Full Text] [Related]
28. Predictive value of pharmaco-electroencephalography in early human-pharmacological evaluations of psychoactive drugs. First example: savoxepine.
Herrmann WM; Schärer E; Delini-Stula A
Pharmacopsychiatry; 1991 Nov; 24(6):196-205. PubMed ID: 1687485
[TBL] [Abstract][Full Text] [Related]
29. Central nervous system effects of haloperidol on THC in healthy male volunteers.
Liem-Moolenaar M; te Beek ET; de Kam ML; Franson KL; Kahn RS; Hijman R; Touw D; van Gerven JM
J Psychopharmacol; 2010 Nov; 24(11):1697-708. PubMed ID: 20142302
[TBL] [Abstract][Full Text] [Related]
30. Pharmaco-EEG profile of maroxepine: third example to discuss the predictive value of pharmaco-electroencephalography in early human pharmacological evaluations of psychoactive drugs.
Herrmann WM; Schärer E; Wendt G; Delini-Stula A
Pharmacopsychiatry; 1991 Nov; 24(6):214-24. PubMed ID: 1812498
[TBL] [Abstract][Full Text] [Related]
31. Classification and determination of cerebral biovailability of psychotropic drugs by quantitative "pharmaco-EEG" and psychometric investigations (studies with AX-A411-BS).
Saletu B; Grünberger J; Linzmayer L
Int J Clin Pharmacol Biopharm; 1977 Oct; 15(10):449-59. PubMed ID: 21853
[TBL] [Abstract][Full Text] [Related]
32. Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol.
Liem-Moolenaar M; Gray FA; de Visser SJ; Franson KL; Schoemaker RC; Schmitt JA; Cohen AF; van Gerven JM
J Psychopharmacol; 2010 Jan; 24(1):73-82. PubMed ID: 18755817
[TBL] [Abstract][Full Text] [Related]
33. Pharmaco-EEG studies with fluperlapine.
Matejcek M; Neff G; Tjeerdsma H; Krebs E
Arzneimittelforschung; 1984; 34(1A):114-20. PubMed ID: 6145426
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and CNS pharmacodynamics of the 5-HT1A agonist buspirone in humans following acute L-tryptophan depletion challenge.
Jagannathan V; Venitz J
Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):351-62. PubMed ID: 9379784
[TBL] [Abstract][Full Text] [Related]
35. Clovoxamine and fluvoxamine-2 biogenic amine re-uptake inhibiting antidepressants: quantitative EEG, psychometric and pharmacokinetic studies in man.
Saletu B; Grünberger J; Rajna P; Karobath M
J Neural Transm; 1980; 49(1-2):63-86. PubMed ID: 6777458
[TBL] [Abstract][Full Text] [Related]
36. Modulating sensorimotor gating in healthy volunteers: the effects of desipramine and haloperidol.
Oranje B; Kahn RS; Kemner C; Verbaten MN
Psychiatry Res; 2004 Jul; 127(3):195-205. PubMed ID: 15296819
[TBL] [Abstract][Full Text] [Related]
37. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments.
García-Gea C; Martínez-Colomer J; Antonijoan RM; Valiente R; Barbanoj MJ
J Clin Psychopharmacol; 2008 Dec; 28(6):675-85. PubMed ID: 19011437
[TBL] [Abstract][Full Text] [Related]
38. Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration.
Farré M; Roset PN; Llorente M; Márquez M; Albet C; Pérez JA; Herrero E; Ortíz JA
Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):343-50. PubMed ID: 9379783
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers.
Barbanoj MJ; García-Gea C; Antonijoan R; Izquierdo I; Donado E; Pérez I; Solans A; Jané F
Hum Psychopharmacol; 2006 Jan; 21(1):13-26. PubMed ID: 16389668
[TBL] [Abstract][Full Text] [Related]
40. BMS-181168 for protection of the human brain against hypoxia: double-blind, placebo-controlled EEG mapping studies.
Saletu B; Schulz H; Herrmann WM; Anderer P; Shrotriya RC; Vanbrabant E
Pharmacopsychiatry; 1994 Sep; 27(5):189-97. PubMed ID: 7838889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
